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Leukocytes in tubulointerstitial 
inflammation
J Hughes1
The work of Lange-Sperandio et al in this issue explores the 
differential role of β2 integrins in promoting the macrophage 
infiltration characteristic of the obstructed kidneys of neonatal mice. 
Future work is needed to define factors that regulate macrophage 
death within or emigration from the kidney as well as to explore 
strategies to modulate macrophage phenotype. This knowledge will 
assist the development of novel therapeutic agents to limit injury 
and promote tissue repair.
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Macrophages are multifunctional cells 
and are key players in the initiation, 
progression, and resolution of infl am-
mation. In particular, infi ltrating mac-
rophages play an important role in the 
etiology and progression of tubulointer-
stitial infl ammation irrespective of the 
nature of the original renal insult.1,2
In this issue, Lange-Sperandio et al 
have examined the role of β2 integrins 
in the striking macrophage infi ltration 
that occurs in experimental obstructive 
nephropathy induced by unilateral uret-
eric ligation.3 Because murine nephrons 
continue to develop during the postnatal 
period, the authors used a neonatal model 
of obstructive nephropathy, as this is rel-
evant to congenital renal tract obstruc-
tion in humans. Indeed, congenital 
human obstructive nephropathy is char-
acterized by increased expression of the 
chemokine monocyte chemoattractant 
protein and signifi cant infi ltration with 
monocytes and macrophages.4 In their 
study, Lange-Sperandio et al obstructed 
the kidneys of neonatal mice (48 hours 
old) targeted for the deletion of either 
myeloid cell–associated marker CD11b 
(Mac-1; CD11b/CD18) or lymphocyte 
function-associated antigen-1 (LFA-
1; CD11a/CD18), adhesion molecules 
that can interact with various counter-
receptors such as intercellular adhesion 
molecule-1 (ICAM-1) on the endothe-
lial-cell surface. Mice were studied at 
days 1, 5, and 12 aft er ureteric obstruc-
tion, and signifi cant diff erences between 
Mac-1–/– and LFA-1–/– mice became evi-
dent. It should be noted that these mice 
do not have reduced circulating leuko-
cyte numbers, so the trivial explanation 
for the fi ndings is excluded. Compared 
with wild-type controls, Mac-1–/– mice 
showed signifi cant protection from mac-
rophage infi ltration at all time points, and 
LFA-1–/– mice exhibited early protection 
at days 1 and 5, with ‘catch-up’ occur-
ring by day 12. Interestingly, despite a 
signifi cant reduction in the early mac-
rophage infi ltrate in both Mac-1–/– and 
LFA-1–/– mice, only Mac-1–/– mice exhib-
ited a signifi cant reduction in the level of 
tubular-cell apoptosis and tubular atro-
phy. Also, Mac-1–/– mice developed less 
interstitial fi brosis, whereas LFA–/– mice 
were not protected from scarring. Th e 
time course of expression of various β2 
integrin counter-receptors, including 
ICAM-1, receptor for advanced glycation 
end products (RAGE), and junctional 
adhesion molecule-C, was examined. 
ICAM-1 and RAGE were predominantly 
expressed early in the model (24 hours), 
whereas the expression of junctional 
adhesion molecule-C, a ligand only for 
Mac-1, increased steadily over the 12-day 
time course. Immunoprecipitation stud-
ies also indicated that RAGE interacted 
preferentially with Mac-1 rather than 
LFA-1.
Th is work extends the previous work 
of this group by demonstrating that β2 
integrins play a pivotal role in the evo-
lution of tubulointerstitial macrophage 
infi ltration, with Mac-1 playing a more 
dominant role than LFA-1. Th e delayed 
upregulation of the Mac-1-specifi c lig-
and junctional adhesion molecule-C 
accounts for the late protection from 
macrophage infiltration afforded by 
Mac-1 deficiency and the delayed, 
though impressive, macrophage infl ux 
evident in LFA-1–/– mice.
As is always the case in experimen-
tal research, this study raises several 
questions worthy of consideration. For 
example, LFA-1–/– mice exhibited a dis-
sociation between the degree of macro-
phage infi ltration (signifi cantly reduced) 
and the level of tubular-cell apoptosis at 
day 5 (comparable to that in wild-type 
controls). Th is is somewhat unusual, as 
multiple previous studies of obstruc-
tive nephropathy have generally noted 
a significant correlation between the 
degree of macrophage infi ltration and 
the level of tubular-cell apoptosis such 
that manipulations that reduce mac-
rophage infi ltration limit tubular-cell 
death. A possible explanation for this 
fi nding is that the infi ltrating macro-
phage population in the LFA-1–/– mice 
may have a more proinflammatory 
and therefore proapoptotic phenotype 
than the macrophages present in wild-
type mice, such that infi ltrating LFA-
1–/– macrophages would be capable of 
inducing greater ‘tubular-cell death 
per macrophage’. It would therefore be 
of interest to examine the activation 
status of the infi ltrating macrophages 
in the various experimental groups, 
especially with respect to expression of 
inducible nitric oxide synthase, as mac-
rophage-derived NO is eminently capa-
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ble of inducing apoptosis in various cell 
types, including resident renal cells.5 
Th ere are experimental precedents for 
such a scenario. For example, blockade 
of CC chemokine ligand 5/RANTES is 
very eff ective at reducing the number 
of infi ltrating macrophages in experi-
mental glomerulonephritis. Glomerular 
injury, however, was actually increased 
in mice treated with the chemokine 
antagonist, and this resulted, at least in 
part, from augmented glomerular mac-
rophage expression of inducible nitric 
oxide synthase.6
Th e study by Lange-Sperandio et al3 
raises questions regarding the exact 
location of the sites of macrophage emi-
gration from the vasculature into the 
renal parenchyma. Th ese sites have still 
to be clearly defi ned, but the localiza-
tion of junctional adhesion molecule-C 
expression to the aff erent and eff erent 
arterioles of the juxtaglomerular appa-
ratus suggests that they are likely to be 
involved in signifi cant monocyte traf-
fi cking. It is also notable that counter-
receptors for monocyte/macrophage 
cell surface integrins are also expressed 
by non-endothelial cells such as tubular 
epithelial cells, and such expression may 
play a role in the maintenance of the 
infi ltrating macrophage population.
In addition, we have very scant infor-
mation regarding the eventual fate of 
infi ltrating macrophages. Previous lim-
ited work examining this question sug-
gests that macrophages may either die 
within the renal parenchyma by under-
going apoptosis or emigrate to draining 
lymph nodes. It is therefore pertinent 
that an increased number of lymphatic 
vessels has been demonstrated within 
the infl amed rodent kidney,7 but it is 
currently unclear whether these are 
involved in large-scale macro phage 
emigration from the diseased kid-
ney. Th us, we have little information 
at present as to what may drive either 
macrophage apoptosis or emigration 
during disease — processes that would 
regulate the time of residence of macro-
phages within infl amed kidneys. Th us, 
although the study and quantifi cation 
of macrophage infi ltration at discrete 
time points during the course of renal 
infl ammation is informative, it remains 
a somewhat simplistic ‘snapshot’ and 
provides no data as to the rate of infl ux 
of macrophages into the tissue or the 
rate of macrophage effl  ux. It may there-
fore be the case that the macrophages 
of Mac-1–/– and LFA–/– mice do exhibit 
diff ering times of residence within the 
interstitium. This area remains to be 
explored by the application of modern 
small-animal imaging and cell labeling 
techniques that will generate ‘real-time’ 
insights into the kinetics of macrophage 
traffi  cking in experimental models of 
renal infl ammation.
Although the model of obstructive 
nephropathy used by Lange-Sperandio 
et al is biologically complicated and 
involves a variety of cell types and a host 
of mediators, it remains the case that 
infl ammatory macrophages are criti-
cally important cells and adversely aff ect 
outcome. It can therefore be appreci-
ated that the infi ltrating macrophage 
represents a potential and very logical 
therapeutic target in tubulointerstitial 
infl ammation. Th e current and previous 
work of Lange-Sperandio and colleagues 
demonstrates the critical involvement 
of β2 integrins and selectins in neonatal 
obstructive nephropathy. Such studies 
incrementally advance our understand-
ing of the mechanisms underlying mac-
rophage adhesion to renal endothelial 
cells and the resultant monocytic infi l-
tration into the renal parenchyma and 
provide the potential to intervene in 
these processes. However, modulation 
of macrophage adhesion/infi ltration is 
not the only area of macrophage biology 
that may be exploited for future thera-
peutic intervention (Figure 1). Much 
work has focused on the chemokines 
involved in monocyte recruitment to 
sites of infl ammation, and antagonists 
to key chemokines have proved effi  ca-
cious in reducing macrophage infi ltra-
tion and ameliorating renal injury in 
various acute and chronic experimental 
models. Th us it appears that strategies 
based on the inhibition of chemokines 
or molecules involved in the adhesion 
and transmigration of monocytes may 
well be of use in the clinical setting.
Patients, however, typically present 
with established disease such that their 
kidneys are infi ltrated with signifi cant 
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Figure 1 | Schema indicating potential sites of therapeutic intervention to inhibit monocyte 
recruitment and infiltration, reduce macrophage numbers within the kidney, or modify the 
phenotype of the infiltrating macrophage population. IL, interleukin; IL-1Ra, interleukin-1 
receptor antagonist.
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numbers of infl ammatory macrophages, 
and modulation of this established inju-
rious cell population may well be of 
benefi t. Our recent work used a model 
of conditional macrophage ablation in 
which the administration of minute 
doses of diphtheria toxin to mice trans-
genic for the human diphtheria toxin 
receptor under the CD11b promoter 
effectively ablates circulating mono-
cytes and renal macrophages. Ablation 
of monocytes/macrophages between 
days 15 and 20 of experimental crescen-
tic glomerulonephritis improved renal 
function and reduced the level of tubu-
lar-cell apoptosis and fi brosis.8 Th us, the 
targeted induction of apoptosis of infi l-
trating macrophages may be benefi cial 
in renal infl ammation.
An alternative means to reduce inter-
stitial macrophage numbers is to inhibit 
macrophage proliferation, as tubular 
cells are a rich source of the mitogen 
macrophage colony-stimulating factor, 
which supports macrophage prolifera-
tion.9 Also, as an alternative to attempt-
ing to reduce macrophage infi ltration, 
the administration of genetically modi-
fi ed macrophages has been attempted, 
with the macrophage being used as a 
‘Trojan horse’ to deliver anti-infl amma-
tory mediators such as interleukin-10 
or interleukin-1 receptor antagonist to 
the kidney.10 Benefi cial outcomes have 
been obtained in both glomerulone-
phritis and obstructive nephropathy.1,10 
Indeed, interleukin-10 released by the 
interleukin-10-overexpressing mac-
rophages localizing to the kidney may 
exert favorable eff ects on bystander host 
macrophages and facilitate their ‘repro-
gramming’ such that they adopt a less 
injurious phenotype.
We are slowly gaining a deeper under-
standing of the factors that govern 
monocyte recruitment and subsequent 
infiltration into the inflamed renal 
parenchyma, and the work of Lange-
Sperandio and colleagues3 adds to that 
knowledge. Although key questions 
have yet to be addressed, it is envisaged 
that manipulation of macrophage infi l-
tration, death, emigration, and pheno-
type may provide novel future strategies 
to limit infl ammatory injury and pro-
mote tissue repair.
REFERENCES
1. Kluth DC, Erwig L-P, Rees AJ. Multiple facets of 
macrophages in renal injury. Kidney Int 2004; 66: 
542–557.
2. Eardley KS, Cockwell P. Macrophages and 
progressive tubulointerstitial disease. Kidney Int 
2005; 28: 437–455.
3. Lange-Sperandio B, Schimpgen K, Rodenbeck 
B et al. Distinct roles of Mac-1 and its counter-
receptors in neonatal obstructive nephropathy. 
Kidney Int 2006; 69: 81–88. 
4. Grandaliano G, Gesualdo L, Bartoli F et al. MCP-1 
and EGF renal expression and urine excretion 
in human congenital obstructive nephropathy. 
Kidney Int 2000; 58: 182–192.
5. Kipari TMJ, Hughes J. Macrophage-mediated 
renal cell death. Kidney Int 2002; 61: 760–761.
6. Anders HJ, Frink M, Linde Y et al. CC chemokine 
ligand 5/RANTES chemokine antagonists 
aggravate glomerulonephritis despite reduction 
of glomerular leukocyte infiltration. 
J Immunol 2003; 170: 5658–5666.
7. Matsui K, Nagy-Bojarsky K, Laakkonen P et al. 
Lymphatic microvessels in the rat remnant 
kidney model of renal fibrosis: aminopeptidase 
P and podoplanin are discriminatory markers for 
endothelial cells of blood and lymphatic vessels. 
J Am Soc Nephrol 2003; 14: 1981–1989.
8. Duffield JS, Tipping PG, Kipari T et al. Conditional 
ablation of macrophages halts progression of 
crescentic glomerulonephritis. Am J Pathol 2005; 
167: 1207–1219.
9. Isbel NM, Hill PA, Foti R et al. Tubules are the 
major site of M-CSF production in experimental 
kidney disease: correlation with local 
macrophage proliferation. Kidney Int 2001; 60: 
614–625.
10. Yamagishi H, Yokoo T, Imasawa T et al. Genetically 
modified bone marrow-derived vehicle cells 
site specifically deliver an anti-inflammatory 
cytokine to inflamed interstitium of obstructive 
nephropathy. J Immunol 2001; 166: 609–616.
Role of the aldosterone-sensitive 
distal nephron in the sodium 
retention associated with liver 
cirrhosis
CA Ecelbarger1,2
The renal mechanisms underlying sodium retention during liver 
cirrhosis have been difficult to elucidate. Kim and associates describe 
a biphasic pattern of regulation of the renal epithelial sodium 
channel in the common bile duct ligation model, shedding some 
light on this issue.
Kidney International (2006) 69, 10–12. doi:10.1038/sj.ki.5000095
There has been some controversy as 
to the role of regulation of the renal 
sodium transporters and channels in the 
development of edema in animal mod-
els of cirrhosis. In a paper presented in 
this issue, Kim et al1demonstrate the 
complex and perhaps ‘biphasic’ nature 
of this regulation with regard to the 
epithelial sodium channel (ENaC) of 
the distal tubule in the model of com-
mon bile duct ligation (CBDL)-induced 
cirrhosis. Recognition of this apparent 
biphasic renal response to cirrhosis, 
with progression from the early to the 
late phase of decompensation,may help 
to clarify apparent discrepancies in a 
variety of earlier studies.
Sodium retention and liver cirrhosis
Liver cirrhosis is associated with a com-
pensatory stage in which there is evident 
peripheral vasodilation and increased 
cardiac output. In this early stage, there 
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